EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preparation and Preclinical Evaluation of 18F-Labeled Olutasidenib Derivatives for Non-Invasive Detection of Mutated Isocitrate Dehydrogenase 1 (mIDH1)

Roberta Cologni, Marcus Holschbach iD, Daniela Schneider iD, Dirk Bier iD, Annette Schulze, Carina Stegmayr iD, Heike Endepols iD, Johannes Ermert iD, Felix Neumaier iD, Bernd Neumaier iD

Molecules · 21.08.2024 · 29 (16) · 3939

DOI: 10.3390/molecules29163939 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, online erschienen am 21.08.2024. Verfasst von Roberta Cologni und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Neuroscience and Medicine, Nuclear Chemistry (INM-5), Forschungszentrum Jülich GmbH, Wilhelm-Johnen-Straße, 52428 Jülich, Germany. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Fluorine Radioisotopes, Positron-Emission Tomography, Mutation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Helmholtz European Partnering program ("Innovative high-performance computing approaches for molecular neuromedicine").

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations of isocitrate dehydrogenase 1 (IDH1) are key biomarkers for glioma classification, but current methods for detection of mutated IDH1 (mIDH1) require invasive tissue sampling and cannot be used for longitudinal studies. Positron emission tomography (PET) imaging with mIDH1-selective radioligands is a promising alternative approach that could enable non-invasive assessment of the IDH status. In the present work, we developed efficient protocols for the preparation of four 18F-labeled derivatives of the mIDH1-selective inhibitor olutasidenib. All four probes were characterized by cellular uptake studies with U87 glioma cells harboring a heterozygous IDH1 mutation (U87-mIDH) and the corresponding wildtype cells (U87-WT). In addition, the most promising probe was evaluated by PET imaging in healthy mice and mice bearing subcutaneous U87-mIDH and U87-WT tumors. Although all four probes inhibited mIDH1 with variable potencies, only one of them ([18F]mIDH-138) showed significantly higher in vitro uptake into U87-mIDH compared to U87-WT cells. In addition, PET imaging with [18F]mIDH-138 in mice demonstrated good in vivo stability and low non-specific uptake of the probe, but also revealed significantly higher uptake into U87-WT compared to U87-mIDH tumors. Finally, application of a two-tissue compartment model (2TCM) to the PET data indicated that preferential tracer uptake into U87-WT tumors results from higher specific binding rather than from differences in tracer perfusion. In conclusion, these results corroborate recent findings that mIDH1-selective inhibition may not directly correlate with mIDH1-selective target engagement and indicate that in vivo engagement of wildtype and mutated IDH1 may be governed by factors that are not faithfully reproduced by in vitro assays, both of which could complicate development of PET probes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Isocitrate DehydrogenaseFluorine RadioisotopesPositron-Emission TomographyMutationGliomaAnimalsMiceHumansCell Line, TumorRadiopharmaceuticals

Stichwörter der Autor:innen

binding studiesmIDH-selective PET tracerpositron emission tomography (PET)radiofluorination

Substanzen

Isocitrate DehydrogenaseFluorine RadioisotopesFluorine-18RadiopharmaceuticalsIDH1 protein, human

Autor:innen und Institutionen

  • Institute of Neuroscience and Medicine, Nuclear Chemistry (INM-5), Forschungszentrum Jülich GmbH, Wilhelm-Johnen-Straße, 52428 Jülich, Germany.
  • Institute of Radiochemistry and Experimental Molecular Imaging, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
  • Institute of Neuroscience and Medicine, Medical Imaging Physics (INM-4), Forschungszentrum Jülich GmbH, Wilhelm-Johnen-Straße, 52428 Jülich, Germany.
  • Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.

ORCID-Profile: Marcus Holschbach, Daniela Schneider, Dirk Bier, Carina Stegmayr, Heike Endepols, Johannes Ermert, Felix Neumaier, Bernd Neumaier

Förderung

  • Deutsche Forschungsgemeinschaft
  • Helmholtz European Partnering program ("Innovative high-performance computing approaches for molecular neuromedicine")

Zitieren

APA

Cologni, R., Holschbach, M., Schneider, D., Bier, D., Schulze, A., Stegmayr, C., Endepols, H., Ermert, J., Neumaier, F., & Neumaier, B. (2024). Preparation and Preclinical Evaluation of 18F-Labeled Olutasidenib Derivatives for Non-Invasive Detection of Mutated Isocitrate Dehydrogenase 1 (mIDH1). Molecules, 29(16), 3939. https://doi.org/10.3390/molecules29163939

Vancouver

Cologni R, Holschbach M, Schneider D, Bier D, Schulze A, Stegmayr C, et al. Preparation and Preclinical Evaluation of 18F-Labeled Olutasidenib Derivatives for Non-Invasive Detection of Mutated Isocitrate Dehydrogenase 1 (mIDH1). Molecules. 2024;29(16):3939. doi:10.3390/molecules29163939

BibTeX
@article{Cologni2024,
  author = {Cologni, Roberta and Holschbach, Marcus and Schneider, Daniela and Bier, Dirk and Schulze, Annette and Stegmayr, Carina and Endepols, Heike and Ermert, Johannes and Neumaier, Felix and Neumaier, Bernd},
  title = {Preparation and Preclinical Evaluation of 18F-Labeled Olutasidenib Derivatives for Non-Invasive Detection of Mutated Isocitrate Dehydrogenase 1 (mIDH1)},
  journal = {Molecules},
  year = {2024},
  volume = {29},
  number = {16},
  pages = {3939},
  doi = {10.3390/molecules29163939}
}
Kostenlos starten →